17-Dimethylaminoethylamino-17-demethoxygeldanamycinAlvespimycine17-%E3%82%B8%E3%83%A1%E3%83%81%E3%83%AB%E3%82%A2%E3%83%9F%E3%83%8E%E3%82%A8%E3%83%81%E3%83%AB%E3%82%A2%E3%83%9F%E3%83%8E-17-%E3%83%87%E3%83%A1%E3%83%88%E3%82%AD%E3%82%B7%E3%82%B2%E3%83%AB%E3%83%80%E3%83%8A%E3%83%9E%E3%82%A4%E3%82%B7%E3%83%B317-Dimetilaminoetilamino-17-demetoksigeldanamicin17-Dimetilaminoetilamino-17-demetoksigeldanamicinQ4552287
about
sameAs
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumorsHSP90 inhibition by 17-DMAG attenuates oxidative stress in experimental atherosclerosisGeldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat-shock protein 90 kDa after exposure to ionizing radiationA physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cellsDiscovery of the neuroprotective effects of alvespimycin by computational prioritization of potential anti-Parkinson agents.The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathwayThe apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.Heat shock protein inhibitors, 17-DMAG and KNK437, enhance arsenic trioxide-induced mitotic apoptosis.One-electron reduction of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: a pulse radiolysis study
P921
Q28304273-A4605E7F-1E23-4E89-8F1D-700621DDAF54Q28569716-6B4ED655-248A-4FC3-A1E6-3D4D2580407AQ33825349-89BA8539-019B-4C79-BE68-B8DCD50E9868Q34570770-93A17F47-702E-457B-BA5B-E7E344085840Q37123188-88062C52-DC4A-46F5-8069-2B2A0F520EE3Q39048969-27D9A2CD-6CBF-4D2F-9D4C-7F6A4EA9C015Q39051444-DD9B281F-F1C9-4159-80A8-5E3909015465Q39157804-AF9FF43D-13B6-47F9-8C8D-74FDF7D026FFQ39331935-25843E90-BE4E-44CA-BE72-827B5CF87228Q46048549-63D1EAA8-AA1F-4DDD-B17F-59A3251A5767Q84477191-96C78266-C763-45F4-8CCC-A16A7D052144
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
17-Dimetilaminoetilamino-17-demetoksigeldanamicin
@sh
17-Dimetilaminoetilamino-17-demetoksigeldanamicin
@sr
17-ジメチルアミノエチルアミノ-17-デメトキシゲルダナマイシン
@ja
Alvespimycine
@fr
alvespimycin
@en
type
label
17-Dimetilaminoetilamino-17-demetoksigeldanamicin
@sh
17-Dimetilaminoetilamino-17-demetoksigeldanamicin
@sr
17-ジメチルアミノエチルアミノ-17-デメトキシゲルダナマイシン
@ja
Alvespimycine
@fr
alvespimycin
@en
altLabel
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
@en
17-DMAG
@en
17-Demethoxy-17-[[2-(dimethylamino)ethyl]amino]geldanamycin
@en
Alvespimycin
@en
prefLabel
17-Dimetilaminoetilamino-17-demetoksigeldanamicin
@sh
17-Dimetilaminoetilamino-17-demetoksigeldanamicin
@sr
17-ジメチルアミノエチルアミノ-17-デメトキシゲルダナマイシン
@ja
Alvespimycine
@fr
alvespimycin
@en
P592
P638
P646
P661
P662
P683
P1579
P2017
C[C@H]1C[C@@H]([C@@H]([C@H](/C ...... CN(C)C)/C)OC)OC(=O)N)\C)C)O)OC
P2067
P231
467214-20-6
P233
CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)C)OC)OC(=O)N)C)C)O)OC
P234
1S/C32H48N4O8/c1-18-14-22-27(3 ...... t18-,20+,25+,26+,28-,30+/m1/s1
P235
KUFRQPKVAWMTJO-LMZWQJSESA-N
P274
C₃₂H₄₈N₄O₈
P3117
DTXSID00963646
P592
CHEMBL383824
P646
/m/047fcfj
P652
001L2FE0M3